Mandatory reporting of National Average Drug Acquisition Cost, or NADAC, could save Medicaid plans more than $10 billion over a decade, according to a study by Capital Rx and 3 Axis Advisors . CMS currently conducts monthly surveys of drug invoice prices paid by retail pharmacies to produce the NADAC pricing benchmark, which most states rely on for prescription drug payments within their Medicaid programs. Pharmacies aren’t required to respond to the survey, however. To determine the possible economic impact...